Umbilical cord-derived mesenchymal stem cells for treating osteoarthritis of the knee: a single-arm, open-label study

Dilogo, Ismail Hadisoebroto; Canintika, Anissa Feby; Hanitya, Alberto Lastiko; Pawitan, Jeanne Adiwinata; Liem, Isabella Kurnia; Pandelaki, Jacub

doi:10.1007/s00590-020-02630-5

Cited by 41 publications

(53 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has the characteristics of the easy collection, greater proliferative capacity, and less antigenicity [ 20 ]. UC-MSCs have been used to study a variety of refractory diseases, such as diabetic foot [ 27 ], knee osteoarthritis [ 28 ], and premature ovarian failure [ 29 ]. UC-MSCs are becoming another promising MSCs for treating a variety of human refractory diseases.…”

Section: Discussionmentioning

confidence: 99%

Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis

et al. 2020

View full text Add to dashboard Cite

Background: Diabetic nephropathy (DN) is one of the most serious complications of diabetes and the leading cause of end-stage chronic kidney disease. Currently, there are no effective drugs for treating DN. Therefore, novel and effective strategies to ameliorate DN at the early stage should be identified. This study aimed to explore the effectiveness and underlying mechanisms of human umbilical cord mesenchymal stem cells (UC-MSCs) in DN. Methods: We identified the basic biological properties and examined the multilineage differentiation potential of UC-MSCs. Streptozotocin (STZ)-induced DN rats were infused with 2 × 10 6 UC-MSCs via the tail vein at week 6. After 2 weeks, we measured blood glucose level, levels of renal function parameters in the blood and urine, and cytokine levels in the kidney and blood, and analyzed renal pathological changes after UC-MSC treatment. We also determined the colonization of UC-MSCs in the kidney with or without STZ injection. Moreover, in vitro experiments were performed to analyze cytokine levels of renal tubular epithelial cell lines (NRK-52E, HK2) and human renal glomerular endothelial cell line (hrGECs).

show abstract

Section: Discussionmentioning

confidence: 99%

Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…At the short term, the main side effects of the wjMSCs injections were acute synovitis and joint effusion; however, at 12 months of follow-up, the group receiving double MSC injections had significantly reduced pain and improved function as compared to both single MSC doses and double HA injections [ 57 ]. The positive effects on pain reduction and clinical scores with the injection of wjMSCs were confirmed by a recent single-arm study on 29 patients with mild-to-severe OA [ 58 ].…”

Section: Cord Blood and Wharton’s Jelly Mscs For Oa And Ra Therapymentioning

confidence: 76%

Umbilical Cord MSCs and Their Secretome in the Therapy of Arthritic Diseases: A Research and Industrial Perspective

Arrigoni

D’Arrigo

Rossella³

et al. 2020

Cells

View full text Add to dashboard Cite

The prevalence of arthritic diseases is increasing in developed countries, but effective treatments are currently lacking. The injection of mesenchymal stem cells (MSCs) represents a promising approach to counteract the degenerative and inflammatory environment characterizing those pathologies, such as osteoarthritis (OA). However, the majority of clinical approaches based on MSCs are used within an autologous paradigm, with important limitations. For this reason, allogeneic MSCs isolated from cord blood (cbMSCs) and Wharton’s jelly (wjMSCs) gained increasing interest, demonstrating promising results in this field. Moreover, recent evidences shows that MSCs beneficial effects can be related to their secretome rather than to the presence of cells themselves. Among the trophic factors secreted by MSCs, extracellular vesicles (EVs) are emerging as a promising candidate for the treatment of arthritic joints. In the present review, the application of umbilical cord MSCs and their secretome as innovative therapeutic approaches in the treatment of arthritic joints will be examined. With the prospective of routine clinical applications, umbilical cord MSCs and EVs will be discussed also within an industrial and regulatory perspective.

show abstract

“…Apart from the encouraging results described, the use of amnion-based products warrants some considerations in terms of regulatory issues because in most countries, "private banking" of placentas is still forbidden, and the manipulation of these tissues is strictly regulated, with a limited range of clinical applications currently allowed (and OA is usually not among those). Furthermore, other trials have been investigating the role of cultured, umbilical cordederived MSCs in OA, 18,19 thus confirming the great interest toward this source of biological agents.…”

Section: See Related Article On Page 2246mentioning

confidence: 82%

Editorial Commentary: Minimally Invasive Strategies for Osteoarthritis: From Platelets to Mesenchymal Stem Cells

Kon

Matteo

2021

Arthroscopy: The Journal of Arthroscopic & Related Surgery

View full text Add to dashboard Cite

Umbilical cord-derived mesenchymal stem cells for treating osteoarthritis of the knee: a single-arm, open-label study

Cited by 41 publications

References 62 publications

Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis

Human umbilical cord-derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis

Umbilical Cord MSCs and Their Secretome in the Therapy of Arthritic Diseases: A Research and Industrial Perspective

Editorial Commentary: Minimally Invasive Strategies for Osteoarthritis: From Platelets to Mesenchymal Stem Cells

Contact Info

Product

Resources

About